SAN DIEGO, Calif., January 31, 2024 —Bloom Science, Inc., today announced that the United States Patent and Trademark Office (USPTO) and European Patent Office have issued multiple new patents, US 11,883,441 and EP 3558329 (covering 18 countries). The new patents broadly cover pharmaceutical compositions of bacterial strains and methods of using the bacterial strains for therapeutic products to treat seizures. The newly issued patents are exclusively licensed to Bloom Science under an agreement with the Regents of the University of California and provide coverage through at least 2038. These issuances further strengthen Bloom’s leading intellectual property position in the microbiome field, which includes previous issuances of US 11,129,858, JP7166280, and AU2017382197.
“The continued expansion of our intellectual property portfolio further demonstrates Bloom’s leading IP position in the fields of neuro-metabolism and gut-brain axis and provides further recognition of the ground-breaking work of Bloom Science’s co-founder Dr. Elaine Hsiao,” said Christopher Reyes, Ph.D., Chief Executive Officer of Bloom Science.
The new U.S. patent issuances broaden the intellectual property protection coverage for Bloom’s lead drug BL-001 in various epileptic syndrome and other clinical-stage programs.
About Bloom Science
Bloom Science is a clinical-stage company, trailblazing a path to transformative, novel therapeutics for patients with rare and complex neurological and metabolic disorders. Bloom’s proprietary discovery platform, IrisRx™ enables a fundamentally different approach to developing medicines by harnessing our expanding insight into the Gut-Brain Axis to design and develop therapeutics that target novel biology with superior safety profiles. The IrisRx™ platform unlocks the potential for developing multi-functional therapeutics from the most common cell type in the human body, gut commensal microbes, while also utilizing an expanding proprietary knowledge base to advance therapeutic candidates based on synthetic biology. Bloom Science is advancing a deep pipeline of programs, including Dravet syndrome, other rare epilepsies, Amyotrophic Lateral Sclerosis (ALS), and neurodegenerative and cardiometabolic disorders. For more information, visit: https://bloomscience.com/
Forward-Looking Statement
This press release may contain “forward-looking statements,” including statements by Dr. Reyes or other persons on Bloom Science’s behalf and statements regarding Bloom Science’s expectations about any of the following: (i) the safety, efficacy and clinical progress of our various clinical programs, including our BL-001 program; (ii) the status of clinical trials (including activities at clinical trial sites); (iii) the data generated by ongoing and planned clinical trials, and the ability to use that data for the design and initiation of further clinical trials; and (iv) the therapeutic value, development, and commercial potential of Bloom Science Live Biotherapeutic Products. The words “believes,” “anticipates,” “plans,” “expects” and similar expressions are intended to identify forward-looking statements. You are cautioned that forward-looking statements are inherently uncertain. Although Bloom Science believes such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, forward-looking statements are neither promises nor guarantees and are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Bloom Science disclaims any obligation or undertaking to update or revise any forward-looking statements, other than as required by law.